Detailed breakdown of funding by disease and themed area
| Disease | Number of studies | Percentage of mycology studies | Total funding | Percentage of mycology funding | Mean award, £ (SD) | Median award, £ (IQR) | Top funder |
|---|---|---|---|---|---|---|---|
| Mycology | 171 | – | £48 404 484 | – | 283 067 (447 190) | 138 257 (41 162–338 222) | BBSRC |
| Pathogen | |||||||
| Aspergillus | 26 | 15.2 | £4 853 858 | 10.0 | 186 687 (420 903) | 47 948 (19 703–157 829) | NIH |
| Candida | 76 | 44.4 | £22 781 931 | 47.1 | 299 762 (325 500) | 255 162 (82 135–372 676) | BBSRC |
| Cryptococcosis | 9 | 5.3 | £3 481 534 | 7.2 | 386 837 (358 695) | 404 883 (90 007–438 535_ | MRC |
| Paracoccidioides | 4 | 2.3 | £462 478 | 1.0 | 115 619 (49 117) | 110 689 (74 065–157 173) | Wellcome Trust |
| Infection group* | |||||||
| Respiratory | 38 | 22.2 | £8 399 295 | 17.4 | 221 034 (397 440) | 74 155 (23 089–221 162) | Wellcome Trust |
| Dermatology | 5 | 2.9 | £407 005 | 0.8 | 81 401 (108 273) | 49 010 (8588–74 335) | Wellcome Trust |
| STIs | 5 | 2.9 | £339 175 | 0.7 | 67 835 (110 710) | 24 684 (17 076–32 353) | NIH |
*For pathogens with multiple modes of entry and sites of impact, for example, Candida, studies could only be applied to infection groups if they explicitly mentioned the route of transmission or site of infection. This was often not the case particularly with preclinical studies.
BBSRC, Biotechnology and Biological Sciences Research Council; MRC, Medical Research Council; NIH, National Institute of Health; STIs, sexually transmitted infections.